Cargando…

4-1BB (CD137) in anticancer chimeras

4-1BB (CD137, TNFRSF9) mediates costimulatory signals important for activation and persistence of cytotoxic T lymphocytes. In this issue of JEM, Oda et al. (https://doi.org/10.1084/jem.20191166) report on a chimeric construction encompassing extracellular Fas and intracellular 4-1BB to dramatically...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melero, Ignacio, Berraondo, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Rockefeller University Press 2020
Materias:	Insights
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549314/ https://www.ncbi.nlm.nih.gov/pubmed/33147322 http://dx.doi.org/10.1084/jem.20201562

Ejemplares similares

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
por: Zapata, Juan M., et al.
Publicado: (2018)

New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)

CD137 (4-1BB) costimulation of CD8(+) T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
por: Otano, Itziar, et al.
Publicado: (2021)

TB granuloma: CD30 co-stimulation for CD4(+) T cell co-operation
por: Gress, Abigail R., et al.
Publicado: (2023)

CD1a autoreactivity: When size does matter
por: Gapin, Laurent
Publicado: (2021)

4-1BB (CD137) and radiation therapy: A case report and literature review
por: Shiao, Jay C., et al.
Publicado: (2017)

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023)

Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
por: Liu, Guizhong, et al.
Publicado: (2023)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
por: Vinay, Dass S., et al.
Publicado: (2014)

A new chapter in the CD8 T reg story
por: Cantor, Harvey, et al.
Publicado: (2020)

TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation
por: Pichler, Andrea C., et al.
Publicado: (2023)

A mathematical model of combined CD8 T cell costimulation by 4-1BB (CD137) and OX40 (CD134) receptors
por: Konstorum, Anna, et al.
Publicado: (2019)

Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies
por: Glez-Vaz, Javier, et al.
Publicado: (2022)

Tracking the evolutionary rise of C(4) metabolism
por: Sage, Rowan F.
Publicado: (2016)

2,4-D transport and herbicide resistance in weeds
por: Schulz, Burkhard, et al.
Publicado: (2016)

Inhibiting BRD4 to generate BETter T cell memory
por: Kasmani, Moujtaba Y., et al.
Publicado: (2021)

CTLA4 prohibits T cells from cross-dressing
por: Paillon, Noémie, et al.
Publicado: (2023)

Traces of strong selective pressures in the genomes of C(4) grasses
por: Christin, Pascal-Antoine
Publicado: (2017)

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
por: Chen, Siqi, et al.
Publicado: (2019)

CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity
por: Stoll, A., et al.
Publicado: (2021)

Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
por: Bella, Ángela, et al.
Publicado: (2022)

Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism
por: Labiano, Sara, et al.
Publicado: (2014)

JAK1 Selective inhibitors
por: Edwards, Christopher
Publicado: (2021)

TRPA1: An asthma target with a zing
por: Jordt, Sven-Eric
Publicado: (2021)

Blood-thirsty: S1PR5 and T(RM)
por: Hallisey, Victoria M., et al.
Publicado: (2021)

A dark side to NS1 antibodies?
por: Robbiani, Davide F., et al.
Publicado: (2021)

Talin1 sets the stage for dendritic cell activation
por: Clausen, Björn E.
Publicado: (2020)

cDC1 dysregulation in cancer: An opportunity for intervention
por: Gajewski, Thomas F., et al.
Publicado: (2020)

I SPI1 something needed for B cells
por: Wahlster, Lara, et al.
Publicado: (2021)

Fast and scarless: Prx1(+) fibroblasts turbocharge healing
por: Kratofil, Rachel M., et al.
Publicado: (2023)

β-Catenin regulates tumor-derived PD-L1
por: Han, Chuanhui, et al.
Publicado: (2020)

NLRP1 activation by UVB: Shedding light on an enigmatic inflammasome
por: Sandstrom, Andrew
Publicado: (2022)

Takes one to B1a: Dismantling the origin of mantle cell lymphoma
por: Beaudin, Anna E.
Publicado: (2021)

Null IFNAR1 and IFNAR2 alleles are surprisingly common in the Pacific and Arctic
por: Meyts, Isabelle
Publicado: (2022)

ZBP1: A STARGᐰTE to decode the biology of Z-nucleic acids in disease
por: Kesavardhana, Sannula, et al.
Publicado: (2020)

Novel Rht-1 dwarfing genes: tools for wheat breeding and dissecting the function of DELLA proteins
por: Thomas, Stephen G.
Publicado: (2017)

Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8(+) Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy
por: Chacon, Jessica Ann, et al.
Publicado: (2013)

CD137-CD137 Ligand Interactions in Inflammation
por: Kwon, Byungsuk
Publicado: (2009)

Intratumoral immunotherapy with mRNAs encoding chimeric protein constructs encompassing IL-12, CD137 agonists, and TGF-β antagonists
por: Cirella, Assunta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b9kbfs1i60g95jlnm1s7mhv0fn